Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Johnson & Johnson's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 8.63%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Johnson & Johnson's 10-Year ROIIC % or its related term are showing as below:
XSWX:JNJ's 10-Year ROIIC % is ranked better than 61.16% of 860
companies
in the Drug Manufacturers industry
Industry Median: 4.41
vs XSWX:JNJ: 8.63
Johnson & Johnson (XSWX:JNJ) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Johnson & Johnson 10-Year ROIIC % Related Terms
Johnson & Johnson 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Johnson & Johnson's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:JNJ vs ABBV, MRK, AMGN: 10-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Johnson & Johnson's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Johnson & Johnson (XSWX:JNJ) has a 10-Year ROIIC % of 8.63 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Johnson & Johnson and its competitors. According to the industry distribution chart, Johnson & Johnson ranks #334 out of 860 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is Johnson & Johnson's 10-Year ROIIC % too high?
Johnson & Johnson's current 10-Year ROIIC % is 8.63. The Drug Manufacturers industry median 10-Year ROIIC % is 4.41. Johnson & Johnson's value of 8.63 is 95.7% above this industry median. Based on the distribution chart, Johnson & Johnson ranks #334 out of 860 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Johnson & Johnson has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's 10-Year ROIIC % compare to ABBV and MRK?
According to the Drug Manufacturers industry distribution chart, Johnson & Johnson ranks #334 out of 860 companies for 10-Year ROIIC %. This puts Johnson & Johnson in the upper half of its industry. The industry median 10-Year ROIIC % is 4.41. Johnson & Johnson's value of 8.63 is 95.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.41, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Johnson & Johnson's current 10-Year ROIIC % of 8.63 is 95.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Johnson & Johnson and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Johnson & Johnson's current 10-Year ROIIC % is 8.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (XSWX:JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF154.50, compared to a current price of CHF205.10 — trading 32.8% above its estimated fair value. The current 10-Year ROIIC % is 8.63 and 95.7% above the Drug Manufacturers industry median of 4.41. Johnson & Johnson's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Johnson & Johnson (XSWX:JNJ), the current 10-Year ROIIC % is 8.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson & Johnson (XSWX:JNJ) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued.
The current stock price of CHF205.10 is trading 32.8% above its estimated GF Value™ of CHF154.50.
GuruFocus considers Johnson & Johnson to be Significantly Overvalued.
Key valuation signals for XSWX:JNJ:
10-Year ROIIC %: 8.63
GF Value™: CHF154.50 vs. price of CHF205.10 (32.8% above fair value)
Industry Position: 95.7% above the Drug Manufacturers median (#334 of 860)
No single metric tells the full story. See the XSWX:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
76GF Score
Get the complete analysis for XSWX:JNJ
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:JNJ has been successfully added to your 
